Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 13/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20242743 | 1.00 | TOP1 (1.00) | TOP1KCNH2KDM4EALDH1A1LMNA | |
| SCHEMBL20242745 | 1.00 | TOP1 (1.00) | TOP1KCNH2KDM4EALDH1A1LMNA | |
| SCHEMBL21787290 | 0.95 | TOP1 (0.90) | TOP1KCNH2KDM4EALDH1A1LMNA | |
| SCHEMBL20258411 | 0.93 | TOP1 (0.88) | TOP1KCNH2KDM4EALDH1A1LMNA | |
| SCHEMBL20258379 | 0.93 | TOP1 (0.88) | TOP1KCNH2KDM4EALDH1A1LMNA | |
| SCHEMBL20258365 | 0.91 | TOP1 (0.84) | TOP1KCNH2KDM4EALDH1A1LMNA | |
| SCHEMBL20258349 | 0.91 | TOP1 (1.00) | TOP1KCNH2 | |
| SCHEMBL20258378 | 0.91 | TOP1 (1.00) | TOP1KCNH2 | |
| SCHEMBL20258363 | 0.91 | TOP1 (1.00) | TOP1KCNH2 | |
| SCHEMBL21786930 | 0.90 | TOP1 (0.81) | TOP1KCNH2KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981875-B2 | Quinolone-based compounds with anticancer activity | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200071273-A1 | QUINOLONE-BASED COMPOUNDS WITH ANTICANCER ACTIVITY | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2020-03-05 | — | — | US | disclosed |
| WO-2018107112-A1 | QUINOLONE-BASED COMPOUNDS WITH ANTICANCER ACTIVITY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2018-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071273-A1 | QUINOLONE-BASED COMPOUNDS WITH ANTICANCER ACTIVITY | TOP2A, TOP2B, TOP1 | TOP1 3/4885KCNH2 3090/4885KDM4E 1627/4885 |
| US-10981875-B2 | Quinolone-based compounds with anticancer activity | TOP2A, TOP2B, TOP1 | TOP1 3/4885KCNH2 3090/4885KDM4E 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.